Phone:020-31155029| Tech Support:tech@tomums.cn| E-mail:sales@tomums.cn
首页 > 产品 > 活性小分子 > Apoptosis > Navitoclax(ABT-263)

Navitoclax(ABT-263)

商品编号: TL0153
图示 货号 库存 价格(¥) 数量

备注:

库存充足,如需更大包装,请联系销售人员,大包装有极大的折扣优惠!

质量文档

详细介绍

l  基本信息

产品名称

Navitoclax

一般描述

Navitoclax is an antagonist of Bcl-2 family  of proteins with potential antineoplastic activity. Navitoclax selectively  binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w.

别 称

4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide;  ABT-263;ABT 263;

纯 度

≥98%  (HPLC)

CAS NO.

923564-51-6

分子式

C47H55ClF3N5O6S3

分子量

974.611

适用范围

生物试剂,适用于细胞培养等

l  理化信息

外 观

白色或类白色固体

溶解性(25)

DMSO

≥50mg/mL

乙醇

Insoluble

Insoluble

l  生物学信息

生物活性/药理作用

Navitoclax is an orally active, synthetic  small molecule and an antagonist of a subset of the B-cell leukemia 2 (Bcl-2)  family of proteins with potential antineoplastic activity. Navitoclax  selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w,  which are frequently overexpressed in a wide variety of cancers, including  those of the lymph, breast, lung, prostate, and colon, and are ed to  tumor drug resistance. Inhibition of these apoptosis suppressors prevents  their binding to the apoptotic effectors Bax and Bak proteins, thereby  triggering apoptotic processes in cells overexpressing Bcl-2, Bcl-XL, and  Bcl-w. This eventually reduces tumor cell proliferation.

应 用

Antineoplastic Agents

l  包装与存储

包 装

5mg;  10mg; 25mg; 100mg

存储温度

-20

l  注意事项及免责声明

本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。

l  参考文献

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.  https://www.ncbi.nlm.nih.gov